Hexvix (Hexaminolevulinate)

Hexvix is indicated for the detection of non‑muscle invasive bladder cancer during cystoscopic examination.

• Enhances visualization of carcinoma in situ and flat lesions.
• Improves identification of papillary tumors that may be missed under white light.
• Used as an adjunct to standard white‑light cystoscopy to increase diagnostic yield.
• Assists in evaluating recurrence during surveillance cystoscopies.
• Guides targeted biopsy of fluorescent areas for histopathologic confirmation.

• Hexvix contains hexaminolevulinate, a prodrug that enters urothelial cells and is metabolized to protoporphyrin IX within the heme biosynthetic pathway. Malignant cells preferentially accumulate protoporphyrin IX, which fluoresces when illuminated with blue light (380–450 nm). This fluorescence highlights cancerous lesions, allowing clinicians to distinguish them from normal tissue during cystoscopy. The selective accumulation is due to increased activity of enzymes such as porphobilinogen deaminase in dysplastic urothelium, enhancing the diagnostic contrast.

Adverse reactions reported with intravesical Hexvix are generally related to the local administration and the photosensitizing properties of the drug.

Common

• Bladder discomfort or urgency, usually mild and transient.
• Dysuria (painful urination), often resolves within 24 hours.
• Mild hematuria, typically self‑limiting.
• Transient increase in urinary frequency, lasting a few hours.

Serious

• Severe allergic reaction, including anaphylaxis, requiring immediate medical attention.
• Persistent bladder irritation that may need therapeutic intervention.
• Prolonged photosensitivity of the urinary tract, increasing risk of light‑induced damage.

When using Hexvix, clinicians should observe specific precautions to minimize risks associated with intravesical administration and photosensitivity.

• Do not administer to patients with known hypersensitivity to hexaminolevulinate or similar photosensitizers.
• Avoid exposure of the urinary tract to strong blue or ultraviolet light for several hours after the procedure.
• Ensure the bladder is adequately emptied before and after instillation to reduce retention risk.
• Monitor patients for signs of urinary retention and manage promptly if it occurs.
• Use with caution in patients with active urinary tract infection or severe inflammation.
• Consider renal or hepatic impairment as it may affect drug clearance, although data are limited.

Hexvix may interact with other agents that influence photosensitivity or bladder physiology.

Avoid

• Concomitant use of systemic photosensitizers (e.g., porfimer sodium) that could amplify fluorescence.
• Direct exposure of the bladder to strong UV or blue‑light sources after administration.
• Intravesical chemotherapy agents that might interfere with Hexvix uptake or fluorescence.

Use with caution

• Anticholinergic drugs that may affect bladder emptying and increase retention risk.
• Medications that alter heme synthesis pathways, such as high‑dose iron supplements.
• Agents that cause urinary tract irritation, potentially compounding local discomfort.
• Drugs associated with heightened allergic potential, including certain monoclonal antibodies.